OBLON	
SPIVAK	
McClelland	
MAIER	
NEUSTADT	
RC.	

## FACSIMILE '

**MESSAGE** 

TO Examiner Fronda February 24, 2004 NAME PATE USPTO 571 273 0929 COMPANY/FIRM FAX# NUMBER OF PAGES (NCLUDING COVER: CONFIRM FAX: YES NO **FROM** Daniel J. Pereira 203979US NAME OUR REFERENCE 09/903,770 703 412-6560

Reg. 45,518

ATTORNEYS AT LAW 1940 DUKE STREET ALEXANDRIA, VIRGINIA 22314 USA (703) 413-3000 (703) 413-2220 FACSIMILE OBLONPAT@OBLON.COM DIRECT PHONE # YOUR REFERENCE PATENT, TRADEMARK AND COPYRIGHT LAW AND RELATED FEDERAL AND ITC LITIGATION

PLEASE CALL US AT (703) 419-3000 IF THE MESSAGE YOU RECEIVE IS INCOMPLETE OR NOT LEGIELE

WWW,OBLON.COM

As requested, attached is a copy of our Amendment filed on January 30, 2004.

Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile messag is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error or are not sure whether it is privileged, pleas immediately n tify us by telephone and return the original message to us at the above address via the U.S. Postal Service at our Expense. Thank You.

DOCKET NO: 203979US0X

## IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

BETTINA MOECKEL, ET AL. : EXAMINER: FRONDA

SERIAL NO: 09/903,770

FILED: JULY 13, 2001 : GROUP ART UNIT: 1652

FOR: NUCLEOTIDE SEQUENCES CODING FOR THE LYSRI GENE

## AMENDMENT

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Office Action dated October 02, 2003, Applicants request reconsideration in light of the following.

Remarks/Arguments begin on page 2 of this paper.

Application No. 09/903,770
Reply to Office Acti n of October 2, 2003

## REMARKS/ARGUMENTS

Claims 53-68, 72, 73, 77, 78, 81 and 82 are active in this application. Claims 53-58, 62, 68, 72, 73, 77, 78, 81 and 82 are allowed.

Applicants wish to thank Examiner Fronda for discussing the issues in the Office

Action with the undersigned on November 4, 2003. In addition, Applicants thank Examiner

Fronda and SPE Acutamurthy for discussing this case with the undersigned on January 15,

2004.

During the discussion the undersigned pointed out that Claims 67 and 65 are not duplicates because Claim 65 is drawn to a polynucleotide whereas Claim 67 is drawn to vector. Accordingly, withdrawal of the objection under 37 CFR 1.75 is requested.

In addition, the phrase "wherein the polynucleotide encodes protein that inhibits lysine production in a bacterial cell" was discussed. In particular, the undersigned pointed to the description on pages 23-25 where the disruption of the polynucleotide, e.g., SEQ ID NO:1, resulted in an increase in lysine production which means that the intact gene inhibits lysine. The Examiner indicated an understanding of this description and indicated that the rejection would be withdrawn after filing this response. Accordingly, withdrawal of the rejection of Claims 59-61 is requested.

Finally, the rejection under 35 U.S.C. § 112, first paragraph was discussed. In particular, the undersigned noted that one can envision at least 30 consecutive nucleotides of SEQ ID NO:1 since the sequence is clearly described. This was also a point of the discussion held on January 15, 2004. During this discussion, SPE Achutamurthy indicated that he would seek the advice from the Patent Office's Biotech patent specialist, Brian Stanton and inform the undersigned of their decision. On January 27, 2004, SPE Achutamurthy contacted the undersigned by telephone and indicated that Claim 64 is adequately described and thus

Application No. 09/903,770
Reply to Office Action of October 2, 2003

should be allowed. In view of this decision, Claims 65 and 66, which depend from Claim 64 should also be allowed. Accordingly, withdrawal of this ground of rejection is requested.

Applicants submit that the present application is now ready for allowance. Early notification of such allowance is requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Customer Number 22850

Tel: (703) 413-3000 Fax: (703) 413 -2220 Jean-Paul Lavalleye, Ph.D.

Attorney of Record Registration No. 31,451

Daniel I. Pereira, Ph.D. Registration No. 45,518